Severe skeletal muscle damage following the administration of mesalazine to a patient with ulcerative colitis

Tabata, Nobutada; Sugimoto, Keisuke; Ueda, Satoshi; Sakata, Naoaki; Okada, Mitsuru; Miyake, Toshiharu; Shinohara, T; Yagi, Makoto; Satou, Takao; Takemura, Tsukasa

doi:10.1111/j.1442-200x.2009.02935.x

Cited by 3 publications

(1 citation statement)

References 7 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Overall, 186 cases of myalgia associated to mesalazine have been reported to the WHO ADR Uppsala Monitoring Center (VigiBase, 20 December, 2015) (12). Besides the reports available in pharmacovigilance database, only two case report of myalgia/muscular damage occurring after mesalazine administration have been reported in the literature, with detailed case-description, both of them regarding paediatric patients (13,14). In our patient the re-administration of mesalazine and subsequent occurrence of myalgia enforced the causality assessment for the ADR occurrence @ C I C E d i z i o n i I n t e r n a z i o n a l i even if the reason of CPK elevation remained unexplained.…”

Section: Discussionmentioning

confidence: 99%

Mesalazine-induced myalgia and creatine phosphate kinase elevation: case report and review of the literature

Festa¹

2015

RGHN

View full text Add to dashboard Cite

Ulcerative Colitis (UC) is a chronic inflammatory disease of unknown etiology needing lifelong therapy. Mesalazine is the first-line treatment for induction and maintaining remissionin mild-to-moderate forms. It is generally well tolerated but adverse reactions occasionally occur and for this reason are challenging from a diagnostic point of view. We present an unusual case of creatine phosphate kinase (CPK) elevation associated to myalgia following administration of mesalazine for UC. Possible explanations as well as differential diagnoses of myopathies in the setting of Inflammatory Bowel Disease are also discussed.

show abstract

Section: Discussionmentioning

confidence: 99%

Mesalazine-induced myalgia and creatine phosphate kinase elevation: case report and review of the literature

Festa¹

2015

RGHN

View full text Add to dashboard Cite

show abstract

Current awareness: Pharmacoepidemiology and drug safety

2010

Pharmacoepidemiology and Drug

View full text Add to dashboard Cite

In order to keep subscribers up‐to‐date with the latest developments in their field, John Wiley & Sons are providing a current awareness service in each issue of the journal. The bibliography contains newly published material in the field of pharmacoepidemiology and drug safety. Each bibliography is divided into 23 sections: 1 Reviews; 2 General; 3 Anti‐infective Agents; 4 Cardiovascular System Agents; 5 CNS Depressive Agents; 6 Non‐steroidal Anti‐inflammatory Agents; 7 CNS Agents; 8 Anti‐neoplastic Agents; 9 Haematological Agents; 10 Neuroregulator‐Blocking Agents; 11 Dermatological Agents; 12 Immunosuppressive Agents; 13 Autonomic Agents; 14 Respiratory System Agents; 15 Neuromuscular Agents; 16 Reproductive System Agents; 17 Gastrointestinal System Agents; 18 Anti‐inflammatory Agents ‐ Steroidal; 19 Teratogens/fetal exposure; 20 Antidiabetic Agents; 21 Contrast Agents; 22 Bone Conservation Agents; 23 Others. Within each section, articles are listed in alphabetical order with respect to author. If, in the preceding period, no publications are located relevant to any one of these headings, that section will be omitted.

show abstract

Gastrointestinal drugs

Blandizzi¹,

Scarpignato²

2011

Side Effects of Drugs Annual

View full text Add to dashboard Cite

Severe skeletal muscle damage following the administration of mesalazine to a patient with ulcerative colitis

Cited by 3 publications

References 7 publications

Mesalazine-induced myalgia and creatine phosphate kinase elevation: case report and review of the literature

Mesalazine-induced myalgia and creatine phosphate kinase elevation: case report and review of the literature

Current awareness: Pharmacoepidemiology and drug safety

Gastrointestinal drugs

Contact Info

Product

Resources

About